RecruitingNCT06535503Updated Feb 17, 2025

Clinical Characteristics and Outcomes Among STEMI Patients with Cardiogenic Shock At Abu Dhabi City

An observational study in ST Elevation Myocardial Infarction and Cardiogenic Shock, sponsored by Abu Dhabi Health Services Company. Recruiting at 2 sites in United Arab Emirates. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-17.

Sponsored by Abu Dhabi Health Services Company · Observational

From the registry’s dates

Started Jul 2024; still recruiting 2 years 4 months later.

Study type: Observational
Model: Cohort
Time perspective: Retrospective
Enrollment: 400
Ages: 18 Years and older
Sex: All

Study summary

A retrospective study on the clinical characteristics and treatment outcomes of patients admitted with ST-elevation Myocardial Infarction (STEMI) complicated with cardiogenic shock (CS) during admission or CS development during their hospital stay for two tertiary hospitals in Abu Dhabi, UAE, from 2020-2024.

Read the detailed description

Cardiovascular disease (CVD) accounts for 40% of mortality in the UAE, which is higher than the global average. Long-term trends, incidence studies, and best practice guidance on Cardiogenic Shock (CS) with ST-elevation Myocardial infarction (STEMI) in the United Arab Emirates (UAE) and the Gulf Cooperation Council (GCC) are limited.

Through this retrospective study, investigators aim to identify treatment modalities and trends, hospitalization events, and patient demographics and comorbidities which lead to participant recovery or mortality in Sheikh Khalifa Medical City (SKMC) and Sheikh Shakhbout Medical City (SSMC) tertiary hospitals for patients admitted with STEMI and CS or developed CS after hospitalization with STEMI during January 2020-January 2024.[200-400 participants]. Data will be collected from eligible patients' electronic medical records (EMR).

Conditions studied

ST Elevation Myocardial Infarction
Cardiogenic Shock

Browse trials for

Keywords

STEMI
Cardiogenic Shock
Morbidity
Mortality

In context

ST Elevation Myocardial Infarction

850 studies on the registry are indexed under ST Elevation Myocardial Infarction; 197 are open to participants now.

This study's planned enrollment of 400 is above the median of 335 across 297 observational studies indexed under ST Elevation Myocardial Infarction.

Browse ST Elevation Myocardial Infarction studies →

Lead sponsor

Abu Dhabi Health Services Company is the lead sponsor of 9 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Patients with STEMI complicated by cardiogenic shock on admission or after hospitalization were treated in Abu Dhabi city from January 2020 to January 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age more than 18.
STEMI complicated by cardiogenic shock.
Were hospitalized or treated at SSMC or SKMC for STEMI complicated by cardiogenic shock.
Patient admitted between January 2019 to March 2024.

Exclusion criteria

Exclusion Criteria:

Age less than 18.
Shock patient not related to Myocardial infarction.
NSTEMI-related cardiogenic shock.
Patients who were not treated at SSMC or SKMC for the STEMI complicated by cardiogenic shock.
Patient not admitted between January 2019 to March 2024.

Study design

Observational model: Cohort
Time perspective: Retrospective
Enrollment: 400 participants (estimated)
Patient registry: No

Groups and cohorts

Patients with STEMI & Cardiogenic Shock
Patients with STEMI complicated by cardiogenic shock on admission or after hospitalization treated at SKMC \& SSMC, Abu Dhbai

What researchers measure

Primary outcomes

Analyze STEMI patient with CS disease profile
Comorbidities, demographical information, past medical history, morbidity
Time frame: 5 years
Incidence of CS-complicated AMI events
The incidence of CS-complicated AMI events will show an increase over the years because of advanced diagnostic modalities and a clearer definition of CS.
Time frame: 5 years
Analyze treatment outcomes in the targeted population as per the patient profile
Incidence of Mortality
Time frame: 5 years
Analyze STEMI patient with CS disease profile
Incidence of Morbidity
Time frame: 5 years
Analyze treatment outcomes
% of patients who were discharged
Time frame: 5 years

Study locations

2 of 2 sites recruiting

Sheikh Khalifa Medical City (SKMC)
Abu Dhabi, 11001, United Arab Emirates
4 other open studies at this site →
Recruiting
- Abdulmajeed BS Alzubaidi, MD · Contact · aalzubaidi@seha.ae · 0502900663
- Alina Naeem, MD · Contact · alnaeem@seha.ae · 0566089799
- Babiker MB Elsiraj, MD · Contact
- Abdulmajeed BS Alzubaidi, MD · Contact
- Mohammed El Khazendar, MD · Contact
- Yousef S Alabrach, MD · Contact
- Alina Naeem, MBBS · Contact
Recruiting
Sheikh Shakhbout Medical City (SKMC)
Abu Dhabi, 11001, United Arab Emirates
5 other open studies at this site →
Recruiting
- Abdulmajeed BS Alzubaidi, MD · Contact · aalzubaidi@seha.ae · 0502900663
- Babiker MB Elsiraj, MD · Contact · Belsiraj@seha.ae · 0564972830
- Babiker MB Elsiraj, MD · Contact
- Abdulmajeed BS Alzubaidi, MD · Contact
- Mohammed El Khazendar, MD · Contact
- Yousef S Alabrach, MD · Contact
- Alina Naeem, MBBS · Contact
Recruiting

References and documents

Publications

Al-Shamsi S, Regmi D, Govender RD. Incidence of cardiovascular disease and its associated risk factors in at-risk men and women in the United Arab Emirates: a 9-year retrospective cohort study. BMC Cardiovasc Disord. 2019 Jun 17;19(1):148. doi: 10.1186/s12872-019-1131-2. PubMed 31208354 ↗
Akbar H, Foth C, Kahloon RA, Mountfort S. Acute ST-Segment Elevation Myocardial Infarction (STEMI). 2024 Oct 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK532281/ PubMed 30335314 ↗
De Luca L, Olivari Z, Farina A, Gonzini L, Lucci D, Di Chiara A, Casella G, Chiarella F, Boccanelli A, Di Pasquale G, De Servi S, Bovenzi FM, Gulizia MM, Savonitto S. Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes. Eur J Heart Fail. 2015 Nov;17(11):1124-32. doi: 10.1002/ejhf.339. Epub 2015 Sep 4. PubMed 26339723 ↗
Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, Califf RM, Berger PB, Topol EJ. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995 Sep;26(3):668-74. doi: 10.1016/0735-1097(95)00215-p. PubMed 7642857 ↗
Shalaby G, Niazi AK, Khaled S. Cardiogenic Shock Among Patients with Acute ST-Segment Elevation Myocardial Infarction in a Middle Eastern Country: A Single-Center Experience. J Saudi Heart Assoc. 2023 Jan 20;34(4):232-240. doi: 10.37616/2212-5043.1323. eCollection 2022. PubMed 36816794 ↗
Yusufali A, Bazargani N, Muhammed K, Gabroun A, AlMazrooei A, Agrawal A, Al-Mulla A, Hajat C, Baslaib F, Philip J, Gupta P, Bakir S, Krishnan S, Almahmeed W, Alsheikh-Ali A. Opportunistic Screening for CVD Risk Factors: The Dubai Shopping for Cardiovascular Risk Study (DISCOVERY). Glob Heart. 2015 Dec;10(4):265-72. doi: 10.1016/j.gheart.2015.04.008. Epub 2015 Aug 11. PubMed 26271552 ↗

Individual participant data

Plan to share: Yes — The plan is to share the clinical study report with all researchers. We will share the study protocol and case report form if further collaboration is decided while expanding our study.

Supporting information: Clinical study report

Time frame: The data will be available for 5 years after the analysis is completed

Access criteria: REDCap or PI \& Facility Permission

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT06535503
Lead sponsor: Abu Dhabi Health Services Company
Collaborators: Sheikh Shakhbout Medical City, Sheikh Khalifa Medical City
Responsible party: Babiker Mohamed Babiker Elsiraj (Principal Investigator, Cardiology Specialist/Fellow at Sheikh Shakhbout Medical City, Abu Dhabi Health Services Company) — Principal investigator
First posted: Aug 2, 2024
Start date: Jul 1, 2024
Primary completion: Jan 1, 2025
Completion: May 30, 2025 (estimated)
Last update: Feb 17, 2025

Study contacts

Alina Naeem, MBBS

Contact

alnaeem@seha.ae

0097124102534

Babiker Babiker Mohamed Babiker Elsiraj MB Elsiraj, MD

Contact

Belsiraj@seha.ae

0564972830

Abdulmajeed BS Alzubaidi, MD

study chair · Abu Dhabi Health Services Co. -SEHA

Babiker Babiker Mohamed Babiker Elsiraj MB Elsiraj

principal investigator · Sheikh Shakhbout Medical City

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

ST Elevation Myocardial Infarction →

Other studies from this sponsor

Abu Dhabi Health Services Company

Start the discussion